查看完整行情页>>

|

货币单位:美元(USD)

Applied Genetic Technologies Corp. (agtc)

实时(?):
盘后(?):
读取中...
  • -- (--%)
开盘价:-- 最高价:-- 最低价:-- 52周最高价:-- 52周最低价:--
成交量:-- 平均成交量:-- 市值:-- 市盈率:-- 预期市盈率:--
每股收益:-- 贝塔系数:-- 股息:-- 收益率:-- 总股本:--
Ivana Magovcevic-Liebisch Ivana Magovcevic-Liebisch is on the board of Aeglea Biotherapeutics, Inc., Suffolk University, Applied Genetic Technologies Corp. and Alivio Therapeutics and Chief Business Officer & Executive Vice President at Ipsen SA. She previously was Chief Strategy & Development Officer, Executive VP at Axcella Health, Inc., Senior VP & Head-Global Business Development at Teva Pharmaceutical Industries Ltd., Chief Operating Officer & Executive Vice President for Dyax Corp. and Director-Intellectual Property & Patent Counsel at Transkaryotic Therapies, Inc. Ivana Magovcevic-Liebisch received a doctorate from Harvard University, a graduate degree from Suffolk University Law School and an undergraduate degree from Wheaton College (Illinois).
Stephen W. Potter Stephen W. Potter is Chief Business Officer & Vice President at Applied Genetic Technologies Corp. In his past career Mr. Potter held the position of Executive Vice President at Caladrius Biosciences, Inc. and Executive Vice President for NeoStem, Inc. (a subsidiary of Caladrius Biosciences, Inc.), SVP-Operations & Corporate Development at Osiris Therapeutics, Inc. and Senior Vice President-Business Development at Genzyme Corp. He received an undergraduate degree from the University of Massachusetts and an MBA from Harvard Business School.
Anne M. VanLent Founder of AMV Advisors and Technology Compass Group LLC, Anne M. VanLent is President at AMV Advisors. She is also on the board of International AIDS Vaccine Initiative, Inc., Applied Genetic Technologies Corp., Trevi Therapeutics, Inc. and Vaxart, Inc. She previously occupied the position of Principal at Technology Compass Group LLC, Chief Financial Officer & Executive Vice President at Barrier Therapeutics, Inc., Chief Financial Officer & Senior Vice President at The Liposome Co., Inc. and Executive Vice President-Portfolio Management at Sarnoff Corp. She received an undergraduate degree from Mount Holyoke College.
Ed M. Hurwitz Mr. Ed M. Hurwitz is a Managing Director at MPM Capital LP, Chairman at Viewpoint Therapeutics, Inc., a Manager at Alta Embarcadero Biopharma Partners III LLC and a Managing Director at Precision BioVentures LLC. He is on the Board of Directors at Applied Genetic Technologies Corp., Calistoga Pharmaceuticals, Inc., MacroGenics, Inc., Alta BioPharma Management III LLC, Alta Partners VIII LP and Avid Radiopharmaceuticals, Inc. Mr. Hurwitz was previously employed as an Independent Director by Sunesis Pharmaceuticals, Inc., an Independent Director by CARA Therapeutics, Inc., and Chief Financial Officer & Senior Vice President by Affymetrix, Inc. He also served on the board at Alta Partners Management Corp., FoldRx Pharmaceuticals, Inc. and Taligen Therapeutics, Inc. Mr. Hurwitz earned his JD and MBA degrees from the University of California, Berkeley's Boalt School of Law and Haas School of Business, and his BA in Molecular Biology from Cornell University.
Anne M. VanLent Founder of AMV Advisors and Technology Compass Group LLC, Anne M. VanLent is President at AMV Advisors. She is also on the board of International AIDS Vaccine Initiative, Inc., Applied Genetic Technologies Corp., Trevi Therapeutics, Inc. and Vaxart, Inc. She previously occupied the position of Principal at Technology Compass Group LLC, Chief Financial Officer & Executive Vice President at Barrier Therapeutics, Inc., Chief Financial Officer & Senior Vice President at The Liposome Co., Inc. and Executive Vice President-Portfolio Management at Sarnoff Corp. She received an undergraduate degree from Mount Holyoke College.
Arnold Lewis Oronsky Arnold Lewis Oronsky occupies the position of Chairman at Dynavax Technologies Corp. and Managing Director at InterWest Partners, LLC. Dr. Oronsky is also General Partner for Interwest Venture Management Co. and on the board of 12 other companies. In his past career he held the position of Vice President-Discovery Research at Lederle Laboratories, Head-Inflammation, Allergy & Immunology Research at Ciba-Geigy Corp., Head-Inflammation, Allergy & Immunology at Ciba-Geigy Pharmaceuticals and Vice President-Discovery Research at Wyeth Holdings LLC. Arnold Lewis Oronsky received a doctorate from Columbia University and an undergraduate degree from New York University.
Emmie Chang Emmie Chang founded Camperoo, Inc. She is Secretary for Applied Genetic Technologies Corp. Ms. Chang is also Partner at Foley Hoag LLP. In the past Ms. Chang held the position of Chief Executive Officer for Camperoo, Inc.
Scott E. Koenig Scott E. Koenig founded MacroGenics, Inc. Dr. Koenig holds the position of Chairman of Applied Genetic Technologies Corp. and President, Chief Executive Officer & Director at MacroGenics, Inc. He is also on the board of Biotechnology Innovation Organization, GlycoMimetics, Inc. and The International Biomedical Research Alliance and Member of Cornell University Council. In the past Dr. Koenig was Senior Vice President-Research at Medimmune, Inc., Principal at National Institute of Allergy & Infectious Diseases, Chairman for Children's Research Institute, Inc., Principal at National Institutes of Health and Trustee-Advisory Board at Cornell University. Scott E. Koenig received a doctorate and an undergraduate degree from Cornell University and a doctorate from The University of Texas Health Science Center at Houston.
Susan B. Washer Presently, Susan B. Washer holds the position of President, Chief Executive Officer & Director at Applied Genetic Technologies Corp. Ms. Washer is also on the board of 8 other companies. She previously held the position of President & Chief Executive Officer for Scenic Productions, Inc., Principal at Eli Lilly & Co. and Principal at Abbott Laboratories (Pakistan) Ltd. Ms. Washer received an undergraduate degree from Michigan State University and an MBA from Warrington College of Business Administration.
James Rosen Mr. James Rosen is an Independent Director at Applied Genetic Technologies Corp., a Principal at Intersouth Partners, a Chief Executive Officer at Artizan Biosciences, Inc., a Director-Public Health Foundation at Unc Gillings School of Global Public Health and a Partner at Intersouth Associates VI LLC. He is on the Board of Directors at Applied Genetic Technologies Corp. Mr. Rosen was previously employed as an Equity Research Analyst by Brean Murray & Co., a Principal by Duke University Medical Center, and a Principal by The Robert Wood Johnson Foundation. He also served on the board at Viamet Pharmaceuticals Corp., Advanced Animal Diagnostics, Inc., Viamet Pharmaceuticals, Inc., 480 Biomedical, Inc. and Public Health Foundation. He received his undergraduate degree from Duke University, a graduate degree from Unc Gillings School of Global Public Health and an MBA from Kenan-Flagler Business School.
William E. Aliski William E. Aliski is on the board of Ultragenyx Pharmaceutical, Inc., Applied Genetic Technologies Corp. and X4 Pharmaceuticals, Inc. In his past career he was General Manager-BioMarin Europe at BioMarin Pharmaceutical, Inc. and Vice President & General Manager at BioMarin Europe Ltd. (a subsidiary of BioMarin Pharmaceutical, Inc.), Vice President-Patient & Product Services at Genzyme Corp., Chief Commercial Officer & Senior Vice President at FoldRx Pharmaceuticals, Inc. and Vice President-Commercial Operations at Transkaryotic Therapies, Inc. William E. Aliski received a graduate degree and an undergraduate degree from Boston College and a graduate degree from Harvard Kennedy School of Government.
Scott E. Koenig Scott E. Koenig founded MacroGenics, Inc. Dr. Koenig holds the position of Chairman of Applied Genetic Technologies Corp. and President, Chief Executive Officer & Director at MacroGenics, Inc. He is also on the board of Biotechnology Innovation Organization, GlycoMimetics, Inc. and The International Biomedical Research Alliance and Member of Cornell University Council. In the past Dr. Koenig was Senior Vice President-Research at Medimmune, Inc., Principal at National Institute of Allergy & Infectious Diseases, Chairman for Children's Research Institute, Inc., Principal at National Institutes of Health and Trustee-Advisory Board at Cornell University. Scott E. Koenig received a doctorate and an undergraduate degree from Cornell University and a doctorate from The University of Texas Health Science Center at Houston.
William A. Sullivan Mr. William A. Sullivan is Treasurer, Head-Finance & Accounting at Merrimack Pharmaceuticals, Inc. and an Associate at TA Associates Management LP. Mr. Sullivan was previously employed as Controller by Vette Corp. Mr. Sullivan received his undergraduate degree from Williams College, a graduate degree from Northeastern University and an MBA from Northeastern University.
James Rosen Mr. James Rosen is an Independent Director at Applied Genetic Technologies Corp., a Principal at Intersouth Partners, a Chief Executive Officer at Artizan Biosciences, Inc., a Director-Public Health Foundation at Unc Gillings School of Global Public Health and a Partner at Intersouth Associates VI LLC. He is on the Board of Directors at Applied Genetic Technologies Corp. Mr. Rosen was previously employed as an Equity Research Analyst by Brean Murray & Co., a Principal by Duke University Medical Center, and a Principal by The Robert Wood Johnson Foundation. He also served on the board at Viamet Pharmaceuticals Corp., Advanced Animal Diagnostics, Inc., Viamet Pharmaceuticals, Inc., 480 Biomedical, Inc. and Public Health Foundation. He received his undergraduate degree from Duke University, a graduate degree from Unc Gillings School of Global Public Health and an MBA from Kenan-Flagler Business School.
James Rosen Mr. James Rosen is an Independent Director at Applied Genetic Technologies Corp., a Principal at Intersouth Partners, a Chief Executive Officer at Artizan Biosciences, Inc., a Director-Public Health Foundation at Unc Gillings School of Global Public Health and a Partner at Intersouth Associates VI LLC. He is on the Board of Directors at Applied Genetic Technologies Corp. Mr. Rosen was previously employed as an Equity Research Analyst by Brean Murray & Co., a Principal by Duke University Medical Center, and a Principal by The Robert Wood Johnson Foundation. He also served on the board at Viamet Pharmaceuticals Corp., Advanced Animal Diagnostics, Inc., Viamet Pharmaceuticals, Inc., 480 Biomedical, Inc. and Public Health Foundation. He received his undergraduate degree from Duke University, a graduate degree from Unc Gillings School of Global Public Health and an MBA from Kenan-Flagler Business School.
Arnold Lewis Oronsky Arnold Lewis Oronsky occupies the position of Chairman at Dynavax Technologies Corp. and Managing Director at InterWest Partners, LLC. Dr. Oronsky is also General Partner for Interwest Venture Management Co. and on the board of 12 other companies. In his past career he held the position of Vice President-Discovery Research at Lederle Laboratories, Head-Inflammation, Allergy & Immunology Research at Ciba-Geigy Corp., Head-Inflammation, Allergy & Immunology at Ciba-Geigy Pharmaceuticals and Vice President-Discovery Research at Wyeth Holdings LLC. Arnold Lewis Oronsky received a doctorate from Columbia University and an undergraduate degree from New York University.
Matthew Feinsod Matthew Feinsod founded Imagen Biotech, Inc. Dr. Feinsod occupies the position of Chief Medical Officer at Imagen Biotech, Inc. and EVP-Global Strategy & Development at Applied Genetic Technologies Corp. Dr. Feinsod is also on the board of World Eye Mission. Dr. Feinsod previously held the position of Medical Officer at US Food & Drug Administration, Senior VP-Strategy & Product Development at Eyetech Pharmaceuticals, Inc. and Director-University Hospitals Institutional at George Washington University. Matthew Feinsod received a doctorate from George Washington University and an undergraduate degree from The Wharton School of the University of Pennsylvania.
Mark S. Shearman Currently, Mark S. Shearman is Chief Scientific Officer & Vice President at Applied Genetic Technologies Corp. Dr. Shearman previously occupied the position of Senior Director at Merck Sharp & Dohme Research Laboratories and Senior VP-Research & Early Development at EMD Serono, Inc. Dr. Shearman received an undergraduate degree from the University of Bristol and a doctorate from The University of Nottingham.
Theresa Heah Currently, Theresa Heah occupies the position of Chief Medical Officer of Applied Genetic Technologies Corp. She is also Member of Royal College of Ophthalmologists and Member of The Royal College of Surgeons of Edinburgh. In her past career she was Vice President-Clinical Research & Medical Affairs at Aerie Pharmaceuticals, Inc. Dr. Heah received a doctorate from King's College London.
Rabia Ozden Rabia Ozden occupies the position of Vice President-Clinical Research & Development at Applied Genetic Technologies Corp. Ms. Ozden is also Vice President & Head-Clinical Ophthalmology at GlaxoSmithKline Plc. In her past career she held the position of Executive Medical Director-Ophthalmology at Quark Pharmaceuticals, Inc. She received a doctorate from Hacettepe University.
Lanita C. Scott Lanita C. Scott is VP-Clinical Research & Medical Affairs at Applied Genetic Technologies Corp.
Karen M. Carroll Karen M. Carroll is Vice President-Clinical Development Operations at Applied Genetic Technologies Corp.
Brian Krex Currently, Brian Krex is General Counsel of Applied Genetic Technologies Corp.
Nnenna Ihekoromadu Nnenna Ihekoromadu is VP-Clinical Research & Medical Affairs at Applied Genetic Technologies Corp.